[变应性鼻炎中用于评估变应原免疫治疗的免疫细胞标志物研究进展]
[Research progress of immune cell markers in allergic rhinitis for the evaluation of allergen immunotherapy].
作者信息
Li Handa, Zhang Yi, Tao Zezhang
机构信息
Department of Otolaryngology Head and Neck Surgery，Renmin Hospital of Wuhan University，Wuhan，430060，China.
Department of Otolaryngology Head and Neck Surgery，Beijing Chaoyang Hospital，Capital Medical University.
出版信息
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Mar;38(3):251-255;260. doi: 10.13201/j.issn.2096-7993.2024.03.014.
Allergic rhinitis（AR） is a chronic inflammation of nasal mucosa mediated by IgE, which prevalence is increasing year by year. Allergen immunotherapy（AIT） has been proved to be effective in the treatment of AR. Patients can usually achieve satisfactory clinical remission after the standard course of treatment. At present, sIgE/tIgE is mainly used to evaluate the severity of allergy in patients with AR before immunotherapy, but there is no recognized biomarker for evaluating the efficacy of AIT. Based on the mechanism that immune cells participate in the formation of immune tolerance during AIT, this paper reviews the latest progress of immune cell markers in allergic rhinitis for the evaluation of the efficacy of AIT in recent years, in order to provide a more comprehensive evaluation basis for AR patients during immunotherapy.
变应性鼻炎（AR）是一种由IgE介导的鼻黏膜慢性炎症，其患病率逐年上升。变应原免疫疗法（AIT）已被证明对AR治疗有效。患者在标准疗程治疗后通常可实现满意的临床缓解。目前，sIgE/tIgE主要用于评估免疫治疗前AR患者的过敏严重程度，但尚无公认的评估AIT疗效的生物标志物。基于免疫细胞在AIT过程中参与免疫耐受形成的机制，本文综述近年来变应性鼻炎中免疫细胞标志物在评估AIT疗效方面的最新进展，以便为AR患者免疫治疗期间提供更全面的评估依据。
Zotero 插件